|Bid||92.82 x 800|
|Ask||92.84 x 1000|
|Day's Range||92.29 - 92.86|
|52 Week Range||73.54 - 95.00|
|Beta (3Y Monthly)||0.52|
|PE Ratio (TTM)||18.31|
|Forward Dividend & Yield||2.83 (3.06%)|
|1y Target Est||101.00|
Sanofi (SNY) to prioritize key growth drivers, improve operating efficiencies and generate cost savings. The company discontinues R&D activities in diabetes and cardiovascular segments.
Novartis today announced results from two analyses of real-world experience with Kymriah® (tisagenlecleucel), the only CAR-T cell therapy approved in two distinct indications. These analyses are from a readout of a 15-year post-marketing study that add to and complement the rigor of the Kymriah pivotal trials with evidence of the Kymriah real-world experience in expanded groups of patients. When Kymriah was used in the real-world setting, efficacy and safety were consistent when compared to the pivotal trials, including the 24-month analysis of JULIET in adults with r/r diffuse large B cell lymphoma (DLBCL) and ELIANA in children and young adults with r/r B-cell acute lymphoblastic leukemia (ALL)1-6. The real-world experience data were presented at the 61st American Society of Hematology (ASH) annual meeting.
Gilead (GILD) announces positive long-term data from a mid-stage study on Yescarta in adult patients with refractory large B-cell lymphoma.
Biogen stock popped in mid-October after the biotech company said a broader analysis showed some promise for its Alzheimer's treatment, aducanumab. Is now the time to buy Biogen stock?
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented ...
The Swiss government approved on Friday health insurance coverage for CAR-T cell therapies from Novartis and Gilead Sciences, which can cost hundreds of thousands of dollars per patient. In this form of therapy, patients' white blood cells are genetically modified to attack cancer cells. The health department said the decision covered Novartis's Kymriah and Gilead's Yescarta.
Companies with gene therapy capabilities are becoming more attractive to members of Big Pharma, who are eager to add the technology to their portfolios Continue reading...
The volume of global M&A has already reached $3.6 trillion this year, according to data from Dealogic. As history has shown, it takes just one big signature Merger Monday to symbolize hubris and excess—and it may already have happened.
Novartis research head Jay Bradner said on Thursday the Swiss drugmaker is focusing efforts against spinal muscular atrophy (SMA) on gene therapy Zolgensma and retreating from oral therapy like its molecule LMI070, also called branaplam. Bradner's comment to an investor conference in London comes as cross-town rival Roche has won the U.S. Food and Drug Administration's accelerated priority review for its oral SMA therapy that could result in a decision by May 2020. Analysts as well as Roche have pegged risdiplam as a potential blockbuster with more than $1 billion in annual sales, as it competes with Biogen's Spinraza and Zolgensma, the $2.1 million-per-patient gene therapy for which Novartis won approval last May.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
The companies both hit the dubious roster twice, but are joined by many of the biggest names in the drug industry Continue reading...
Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.
Biogen's (BIIB) shares decline following a rating downgrade by an analyst at Robert W. Baird on concerns related to approval of Alzheimer's disease candidate, aducanumab.
Shares of Astellas Pharma Inc. rose about 1% in premarket trading after the Japanese drugmaker said Monday evening that it plans to acquire Audentes Therapeutics for $3 billion in cash. Audentes is developing gene therapies. Its stock jumped 105% in premarket trading. "This is just another bullish domino for genetic medicine," Raymond James' Steven Seedhouse wrote in a research note. In recent years, there have been a number of high-profile buyouts of companies developing gene therapies, including Roche's $4.8 billion pending acquisition of Spark Therapeutics and Novartis's $8.7 billion purchase of AveXis. Astellas said the boards of both companies have approved the deal. Shares of Astellas have gained 35% year-to-date, while the S&P 500 is up about 24%.
After signing two back-to-back deals with Novartis this year, small Boston-based startup IFM Therapeutics is ramping up its business development with a new incubator.
Swiss drugmaker Novartis's new $90 million cell and gene therapy factory in northern Switzerland is on track to begin commercial production of its cell therapy Kymriah for cancer in 2020. The Swiss factory, as well as a separate French site also being expanded, are central to Novartis's plans to transform Kymriah from a modest $250 million-per-year seller into a $1 billion blockbuster as European demand rises. "We have already started to produce clinical batches at both sites and are on track to begin producing commercial product in 2020," Novartis said.